TELA Bio, Inc. filings document a commercial-stage medical technology business centered on soft-tissue reconstruction and the OviTex product portfolio for hernia repair and abdominal wall reconstruction. Form 8-K reports cover operating and financial results, revenue updates, Regulation FD disclosures, material agreements, debt and equity capital structure, and other material events tied to the company's medical technology operations.
Proxy materials and governance-related 8-Ks record board composition, director appointments and resignations, executive compensation matters, stockholder meeting proposals, inducement and equity-award practices, and Nasdaq listing-compliance disclosures for TELA common stock listed on the Nasdaq Global Market.
TELA Bio, Inc. director Joseph H. Capper acquired 19,801 shares of common stock on October 15, 2026, issued in lieu of cash compensation under the issuer’s Amended and Restated Non-Employee Director Compensation Policy. All shares were fully vested. The reported transaction price was $1.01 per share; Capper directly held 199,628 shares after the transaction.
TELA Bio, Inc. director William J. Plovanic acquired 16,089 shares of common stock on October 15, 2026, issued in lieu of cash compensation under the company's Amended and Restated Non-Employee Director Compensation Policy. The shares were fully vested. The reported transaction price was $1.01 per share, and his direct holdings following the transaction were 60,619 shares.
TELA Bio, Inc. (TELA) stockholders approved an amendment authorizing the Board, in its sole discretion, to combine common shares at a reverse-split ratio from one-for-five to one-for-fifteen. The company said it does not intend to effect the reverse stock split at this time after Nasdaq notified it on October 5, 2026, that it had regained compliance with the minimum bid price requirement for continued listing.
Proposal 1 received 30,515,571 votes for, 80,512 against and 1,737,011 abstentions. Stockholders also approved an adjournment, if necessary, to solicit and vote proxies if Proposal 1 lacked sufficient support, with 30,757,679 votes for, 123,860 against and 1,451,555 abstentions. TELA Bio had 45,143,410 common shares outstanding as of September 8, 2026, the record date.
TELA Bio, Inc. regained compliance with the Nasdaq Global Market’s minimum bid price requirement for continued listing under Nasdaq Listing Rule 5450(a)(1). Nasdaq stated that the matter is now closed.
TELA Bio, Inc. announced that the U.S. Food and Drug Administration granted 510(k) clearance for its Liora Monofilament Scaffold. Liora is a fully resorbable surgical mesh for soft tissue reinforcement and the first fully resorbable synthetic product in TELA Bio’s portfolio designed and produced in-house.
TELA Bio said Liora is also the first implant fully developed in its ISO 8 certified cleanroom in Malvern, Pennsylvania, and that the product expands options available to surgeons and patients for soft tissue reconstruction.
On September 28, 2026, TELA Bio, Inc. entered into a Limited Consent to its Credit Agreement with Perceptive Credit Holdings V, LP, as administrative and collateral agent, and lenders constituting the Required Lenders. Under the consent, the minimum Revenue covenant will not be tested for fiscal quarters ending on or about September 30, 2026, and December 31, 2026.
The Credit Agreement, dated November 13, 2025, provides term loans and other financial accommodations made available by the lenders. The consent changes covenant testing for those two quarter-end periods.
TELA Bio, Inc. (TELA) director Joseph H. Capper reported open-market purchases of the company’s common stock on two consecutive days in September 2026. He bought 50,000 shares on September 16, 2026 at a weighted average price of $1.1653 per share and 25,000 shares on September 17, 2026 at a weighted average price of $1.2212 per share. The purchases were executed across multiple trades, with prices on September 16 ranging from $1.14–$1.20 and on September 17 from $1.19–$1.25 per share, and no Rule 10b5-1 trading plan is reported.
TELA Bio, Inc. (TELA) reports that Nasdaq has notified the company its common stock is subject to delisting from the Nasdaq Global Market after it failed to regain compliance with the $1.00 minimum bid price requirement within the 180-day grace period that ended September 14, 2026. TELA plans to timely request a hearing before a Nasdaq Hearings Panel and present a plan to regain and sustain compliance, which will automatically stay any suspension or delisting during the hearings process. To help restore compliance, TELA has filed a proxy seeking shareholder approval for a reverse stock split at a ratio between 1-for-5 and 1-for-15, to be voted on at a special meeting on October 8, 2026; the company states there is no assurance the proposal will be approved.
TELA Bio, Inc. (TELA) director Joseph H. Capper reported open-market purchases of the company’s common stock on two consecutive days in September 2026. On September 14, 2026 he bought 25,000 shares at a weighted average price of $1.0201 per share in multiple trades priced between $0.9899 and $1.04. On September 15, 2026 he bought an additional 50,000 shares at a weighted average price of $1.0588 per share in multiple trades priced between $1.01 and $1.10. In total, Capper purchased 75,000 shares of TELA Bio common stock in these transactions, and no Rule 10b5-1 trading plan is reported.
TELA Bio, Inc. (TELA) is asking stockholders at an October 8, 2026 virtual special meeting to approve a reverse stock split of its common stock at a ratio between 1‑for‑5 and 1‑for‑15, with the exact ratio and timing to be chosen by the board within one year and the option to abandon the action. The company states that its primary goal is to increase the per‑share trading price to regain compliance with Nasdaq’s $1.00 minimum bid price requirement after receiving a deficiency letter and plans to present this as part of a compliance plan to a Nasdaq Hearings Panel.
As of September 8, 2026, TELA Bio had 45,143,410 shares of common stock outstanding and 200,000,000 shares authorized; the reverse split would reduce outstanding shares but leave authorized shares unchanged, increasing the pool of authorized but unissued shares and potentially diluting existing holders in future issuances. The proxy describes risks that the reverse split may not sustain a higher price, notes the possibility of Nasdaq delisting if compliance is not regained, and states that failure to raise sufficient additional capital could mean the company may not be able to continue as a going concern. A second proposal would allow adjournment of the meeting to solicit additional proxies if there are insufficient votes to approve the reverse split.